Search clinical trials for: MK-0646

Total 2290 results

Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Neuroendocrine Tumors | Metastatic Neuroendocrine Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

Advanced Solid Tumors
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Multiple Myeloma | Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Neoplasm
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Metastatic Colorectal Cancer
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Withdrawn

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Merck Sharp & Dohme LLC

Completed

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Colorectal Cancer
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Breast Neoplasms
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Merck Sharp & Dohme LLC; Commonwealth Foundation for Cancer...

Terminated

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Breast Cancer

United States
University of Kansas
Merck Sharp & Dohme LLC

Completed

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (IMPACT)

Non Small Cell Lung Cancer

United States
Lithuanian University of Health Sciences

Completed

Temporary Hydrostatic Splint Therapy and Its Effects on Occlusal Forces

Temporomandibular Joint Disorders

Lithuania
NCIC Clinical Trials Group
Merck Frosst Canada Ltd.

Completed

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Canada
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Helsinki University Central Hospital

Recruiting

Identifying Reasons for Non-adherence in Patients With Multi-morbidity

Chronic Disease | Medication Adherence | Medication Nonadherence

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

HIV Infections

United States
Assiut University

Unknown

Sphenoorbital Meningioma Management.

Brain Meningioma
Medical University of Vienna

Unknown

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Hormone Refractory Prostate Cancer

Austria
Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Nasser Hanna, M.D.
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Completed

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... and other collaborators

Withdrawn

MK-2206 for Recurrent Malignant Glioma

Malignant Glioma

United States
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
National Taiwan University Hospital

Unknown

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Taiwan
Loyola University
Merck Sharp & Dohme LLC

Completed

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer (MK-0752)

Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Arkadiusz Z. Dudek, MD
Merck Sharp & Dohme LLC; Big Ten Cancer Research Consortium

Completed

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Clear Cell Renal Carcinoma

United States
Nisha Mohindra, MD
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network; Celgene Corporation

Terminated

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Non-Small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Lyvgen Biopharma Holdings Limited
Merck Sharp & Dohme LLC

Recruiting

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Cancer

United States
NYU Langone Health

Active, not recruiting

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; University of California, Los Angeles; University... and other collaborators

Active, not recruiting

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Glioma | Recurrent Malignant Glioma

United States
Johannes Gutenberg University Mainz

Recruiting

Teach Intubation by Novices in Anaesthesiology (TeachIntub)

Larynx | Learning Problem

Germany
Hillier, Sharon, PhD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048 (FAME103)

Pharmacokinetics | Safety

United States
Ain Shams Maternity Hospital

Unknown

Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies

Gynecological Pathologies

Egypt
Tammie L. S. Benzinger, MD, PhD

Enrolling by invitation

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer (MKADAD)

Alzheimer Disease

United States
Cairo University

Not yet recruiting

Evaluation of Premixed Verses Powder/Liquid Bioceramic MTA in Indirect Pulp Capping.

Indirect Pulp Capping
Yaakov Stern
National Institute on Aging (NIA)

Recruiting

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Aging | Mild Cognitive Impairment

United States

3

Subscribe